All feline diagnoses

Your cat was diagnosed with Mammary Carcinoma. 25.4 per 100,000 female cats per year. Third most common feline cancer (after lymphoma and skin cancer). 85-90% malignant — dramatically different from canine (~50% benign). Most common cancer in cats >10 years of age. Compare 7 treatment options for cats including Bilateral Staged Mastectomy, Unilateral Mastectomy, Surgery + Doxorubicin (Adjuvant) — with survival times, costs, and what to expect during treatment.

🐈

Mammary Carcinoma

BreedsSiamese (34% of affected population, younger onset)Persian (16%)
feline

Epithelial

About This Cancer

Mammary carcinoma in cats is a biologically aggressive cancer arising from the milk-producing glands. A critical difference from dogs is that 85–90% of feline mammary tumours are malignant — far higher than the roughly 50% rate in dogs. It is the third most common cancer in cats (after lymphoma and skin tumours) and most frequently affects older, intact (unspayed) females. As in dogs, the risk is dramatically reduced by early ovariohysterectomy. Tumour size is the single most important prognostic factor: tumours smaller than 2 cm carry a significantly better prognosis than larger ones. The cancer tends to spread to the lungs and regional lymph nodes. Siamese cats are overrepresented and may develop the disease at a younger age. Surgery — ideally radical mastectomy (often performed as a staged bilateral procedure) — is the mainstay of treatment, with chemotherapy considered for larger or more advanced tumours.

TNM Staging for Feline Mammary Tumours (Modified)

Clinical TNM staging based on tumour size, lymph node involvement, and distant metastasis. 2025 proposal refines Stage III into IIIA/IIIB/IIIC.

Stage I (T1N0M0)Tumour <2cm, no lymph node involvement, no metastasis. MST ~29 months.
Stage II (T2N0M0)Tumour 2-3cm, no lymph node involvement, no metastasis. MST ~12.5 months.
Stage IIIA (T3N0M0)Tumour >3cm, no lymph node involvement. MST ~9 months.
Stage IIIB (T4N0M0)Direct extension to adjacent tissues, no lymph node involvement.
Stage IIIC (any T, N1, M0)Regional lymph node metastasis. Worst prognosis of Stage III.
Stage IV (any T, any N, M1)Distant metastasis. MST ~1 month.
Prognostic Factors(8)
Tumour sizeSharp prognostic divide at 3cm. <3cm MST ~21 months, >3cm MST ~12 months.(Multiple studies)
Histologic gradeGrade I: baseline. Grade II: HR 5.013. Grade III: HR 9.894. Strongest histologic predictor.(Zappulli et al., 2015)
Lymphovascular invasionHR 2.834 for death. Strong negative prognostic factor.(Zappulli et al., 2015)
Skin ulcerationHR 2.462.(Zappulli et al., 2015)
Lymph node metastasisPresent in ~44% at surgery. Dramatically worsens prognosis.
Ki-67 indexKi-67 >=14% associated with large size, poor differentiation, shorter survival.(PMID 26080833)
HER2 statusHER2-positive: shorter DFI. Parallels human breast cancer biology.(PMC5032681)
Spay statusSpay <6 months: 91% risk reduction. Spay 7-12 months: 86%. After 24 months: minimal benefit. Intact: 7x risk.(Overley et al. 2005 (PMID 16095174))
Minimum Workup(8 steps)
1FNA cytology (usually diagnostic for malignancy)
2Excisional biopsy with histopathology: grade (I-III), lymphovascular invasion, Ki-67 index, HER2 status if available
3Abdominal ultrasound (tumour assessment, lymph node evaluation)
4Thoracic radiographs (pulmonary metastasis screening)
5CT chest if radiographs equivocal or advanced disease
6Regional lymph node assessment (palpation + ultrasound ± FNA)
7CBC, comprehensive chemistry panel
8Baseline renal function (BUN, creatinine, USG) — essential if doxorubicin planned

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Bilateral Staged Mastectomy
~38 mo
Unilateral Mastectomy
~13.8 mo (11.5–15.8)
Surgery + Doxorubicin (Adjuvant)
See notes
Surgery + Carboplatin (Adjuvant)
~14.3 mo
Metronomic Chemotherapy
See notes
Palliation
~1 mo
Palliative Radiation Therapy (Chest Wall Recurrence / Inoperable)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.